Nitesh Kumar, Remya James, Shristi Sinha, Manas Kinra, P.V. Anuranjana, Krishnadas Nandakumar
email@example.com , firstname.lastname@example.org
Nitesh Kumar, Remya James, Shristi Sinha, Manas Kinra, P.V. Anuranjana, Krishnadas Nandakumar*
Department of Pharmacology, Manipal College of Pharmaceutical Sciences,
Manipal Academy of Higher Education, Manipal, Karnataka-576104.
Volume - 14,
Issue - 2,
Year - 2021
Parkinsonism is a neurological disorder associated with a group of various motor-related symptoms such as tremor, rigidity, hypokinesia, defective gait, etc. It is caused by the degeneration of dopaminergic neurons in the nigrostriatal tract. Accompanying various side effects with existing treatment options such as levodopa, selegiline, entacapone limits its usage in weak and aged patients. Considering the adverse reaction with the usage of present medications, there is a need to explore the beneficial effects of products from complementary medicine such as flavonoids. Naringin is one such flavonoid which possesses antioxidant effects along with neuroprotection to the nigrostriatal dopaminergic projecting neurons. Taking this as a clue this study was designed to explore the antiparkinsonian action of naringin in haloperidol-induced catalepsy in Swiss albino mice. In this study, animals were divided into five groups and catalepsy was induced in the mouse by intraperitoneal injection of haloperidol (1.5mg/kg). All the treatments with vehicle or naringin were performed 30 min prior to haloperidol injection. Catalepsy score was used as an indicator of behavior mechanism because of its similarity to PD symptoms, which was determined. Naringin treatment showed a reduction in haloperidol-induced cataleptic scores in both bar test and block test after 1 hour of treatment (except 100mg/kg in bar test) as compared with the normal control group. These effects could be attributed due to either dopamine agonist activity or due to its effect on raising dopamine levels in the nigrostriatal tract. However, the mechanisms behind the neuroprotective effect of naringin are not fully defined. Thus, we can conclude that naringin can protect against drug-induced Parkinson’s disease.
Cite this article:
Nitesh Kumar, Remya James, Shristi Sinha, Manas Kinra, P.V. Anuranjana, Krishnadas Nandakumar. Naringin exhibited Anti-Parkinsonian like effect against haloperidol-induced catalepsy in mice. Research J. Pharm. and Tech. 2021; 14(2):662-666. doi: 10.5958/0974-360X.2021.00118.9
1. Mazzoni P, Shabbott B, Cortés JC. Motor control abnormalities in Parkinson’s disease. Cold Spring Harb Perspect Med. 2012 Jun;2(6): a009282.
2. Kumar SB. Role of Caffeine in Dementia, Alzheimer’s, Parkinsonism, Bipolar Mood Disorder. Res J Pharm Technol. 2015;8(11):1582–7.
3. Kahale VP, Upadhay PR, Mhaiskar AJ, Shelat PS, Mundhada DR. To Access the Efficacy of Rutin on 6-Hydroxydopamine induced Animal Model of Memory Impairment in Parkinson’s Disease. Res J Pharmacol Pharmacodyn. 2013;5(6):331–6.
4. Alexander GE. Biology of Parkinson’s disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. Dialogues Clin Neurosci. 2004 Sep;6(3):259–80.
5. Roth RH. Biochemical pharmacology of midbrain dopamine neurons. Psychopharmacol fourth Gener Prog. 1995;
6. Kaminski TW, Karbowska M, Pawlak D. A Review of the Pharmacological properties of potential drugs for the treatment of stuttering from the past to the future. Asian J Pharm Res. 2018;8(2):104–9.
7. Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res. 2004;318(1):121–34.
8. Barone P. Neurotransmission in Parkinson’s disease: Beyond dopamine. Eur J Neurol. 2010;17(3):364–76.
9. Ajit VK, Arun GK, Piush K, Rakesh P. Formulation and Development of Floating Microspheres containing Levodopa and Carbidopa. Asian J Pharm Technol. 2018;8(4):200–2.
10. Prasad J, Netam AK, Singh R, Sahu M, Satapathy T, Rao SP, et al. Therapeutic Approaches for the Management of Parkinson’s disease. Res J Pharmacol Pharmacodyn. 2019;11(1):46–52.
11. Nimitha V, Venkataswamy M, Vaishnavi P, Manisha MS, Swathi V, Saritha R. Medicinal Plants used for the Treatment of Parkinson’s Disease. Res J Pharm Dos Forms Technol. 2019;11(2):134–6.
12. Rouseff RL, Youtsey CO, Martin SF. Quantitative Survey of Narirutin, Naringin, Hesperidin, and Neohesperidin in Citrus. J Agric Food Chem. 1987 Nov;35(6):1027–30.
13. Asahina Y, Inubuse M. Flavanone glucosides. II. Constitution of naringenin. Ber Dtsch Chem Ges B. 1928;61: 1514–6.
14. Horowitz RM, Gentili B. Taste and Structure in Phenolic Glycosides. J Agric Food Chem. 1969 Jul;17(4):696–700.
15. Bharti S, Rani N, Krishnamurthy B, Arya DS. Preclinical evidence for the pharmacological actions of naringin: A review. Planta Med. 07.04.2014. 2014;80(6): 437–51.
16. Jung UJ, Leem E, Kim SR. Naringin: A Protector of the Nigrostriatal Dopaminergic Projection. Exp Neurobiol. 2014;23(2):124.
17. Ahmed S, Khan H, Aschner M, Hasan MM, Hassan STS. Therapeutic potential of naringin in neurological disorders. Food Chem Toxicol. 2019;132: 110646.
18. Suseem SR, Joseph D. The Myth and the fact on Naringin-A Review. Res J Pharm Technol. 2019;12(1): 367–74.
19. Rong W, Wang J, Liu X, Jiang L, Wei F, Hu X, et al. Naringin treatment improves functional recovery by increasing BDNF and VEGF expression, inhibiting neuronal apoptosis after spinal cord injury. Neurochem Res. 2012;37(8): 1615–23.
20. Kuschinsky K, Hornykiewicz O. Effects of morphine on striatal dopamine metabolism: possible mechanism of its opposite effect on locomotor activity in rats and mice. Eur J Pharmacol. 1974;26(1): 41–50.
21. Banasikowski TJ, Beninger RJ. Haloperidol conditioned catalepsy in rats: a possible role for D1-like receptors. Int J Neuropsychopharmacol. 2012 Nov;15(10): 1525–34.
22. Nitin M, Prasad K, Dastapur A, Suryawanshi S. Influence of Vitamin-C on Phenothiazine Induced Extrapyramidal Symptoms in Rats. Res J Pharmacogn Phytochem. 2011;3(1): 22–5.
23. Nitin M, Prasad K, Dastapur A, Suryawanshi S. Influence of Coenzyme Q10 on Phenothiazine Induced Extrapyramidal Symptoms in Rats. Res J Pharmacol Pharmacodyn. 2010;2(3): 248–51.
24. Li P, Snyder GL, Vanover KE. Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future. Curr Top Med Chem. 2016;16(29): 3385–403.
25. Ramalingayya G, Nampoothiri M, Nayak P, Kishore A, Shenoy R, Rao C, et al. Naringin and rutin alleviates episodic memory deficits in two differentially challenged object recognition tasks. Pharmacogn Mag. 2016 Jan;12(45): 63–70.
26. Remya C, Dileep K V, Tintu I, Variyar EJ, Sadasivan C. Flavanone glycosides as acetylcholinesterase inhibitors: computational and experimental evidence. Indian J Pharm Sci. 2014;76(6): 567–70.
27. Youdim KA, Qaiser MZ, Begley DJ, Rice-Evans CA, Abbott NJ. Flavonoid permeability across an in-situ model of the blood–brain barrier. Free Radic Biol Med. 2004;36(5): 592–604.
28. Youdim KA, Dobbie MS, Kuhnle G, Proteggente AR, Abbott NJ, Rice‐Evans C. Interaction between flavonoids and the blood–brain barrier: in vitro studies. J Neurochem. 2003;85(1): 180–92.
29. Tsai T-H. Determination of naringin in rat blood, brain, liver, and bile using microdialysis and its interaction with cyclosporin a, a p-glycoprotein modulator. J Agric Food Chem. 2002;50(23): 6669–74.